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2Abstract
Acylpeptide hydrolase (APEH) deacetylates N-alpha-acetylated peptides and 
selectively degrades oxidised proteins, but the biochemical pathways that are 
regulated by this protease are unknown. Here, we identify APEH as a component 
of the cellular response to DNA damage. Although APEH is primarily localised in 
the cytoplasm, we show that a sub-fraction of this enzyme is sequestered at sites 
of nuclear damage following UVA irradiation or following oxidative stress. We 
show that localization of APEH at sites of nuclear damage is mediated by direct 
interaction with XRCC1, a scaffold protein that accelerates the repair of DNA 
single-strand breaks. We show that APEH interacts with the amino-terminal 
domain of XRCC1, and that APEH facilitates both single-strand break repair and 
cell survival following exposure to H2O2 in human cells. These data identify APEH 
as a novel proteolytic component of the DNA damage response. 
1. Introduction
Alpha acetylation of the amino-terminal amino acid of proteins (Nα-acetylation) is a 
common protein post-translational modification in eukaryotes, occurring on 50-90% of 
proteins [1,2]. Although the precise role of this modification is unclear, it is 
evolutionarily conserved and is required for a broad range of protein functions and 
cellular processes. For example, in budding yeast, Nα-acetylation of Orc1 and Sir3 is 
required to maintain gene silencing, demonstrating an important role for Nα-acetylation 
in regulating chromatin structure [3,4]. In the case of Sir3, Nα-acetylation is required 
for binding unmethylated H3K79 and thus targeting of Sir3 to appropriate genomic 
sites in order to establish heterochromatin [5,6]. In addition, in human cells, Bcl-xL 
controls the level of Nα-acetylation of key apoptotic mediator proteins and thereby 
regulates apoptosis [7].
In contrast to the acetylation of amino acid side chains, Nα-acetylation of 
peptide amino termini is not reversible. However, cellular levels of Nα-acetylation are 
regulated by a cytosolic serine protease denoted acylpeptide hydrolase (APEH), which 
can remove the Nα-acetylated amino-terminal amino acid from oligopeptides [8] and 
decreases the extent of Nα-acetylation in many proteins [9]. Intriguingly, APEH also 
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also denoted oxidised protein hydrolase [10,11]. It is currently unclear whether the 
endo/exopeptidase activity of APEH is dependent on its acylpeptide hydrolase activity 
but, in support of this idea, the loss of Nα-acetylation destabilises and/or promotes 
proteolysis of some proteins [12,13]. Recently, APEH was also reported to regulate the 
activity of the proteosome [14].
Loss or inhibition of APEH activity is implicated in elevated T cell proliferation 
and small cell lung cancer [9,15]. However, the biochemical pathways that are 
regulated by APEH are unknown. Here, we show that APEH is a component of the 
cellular response to chromosomal DNA damage, following oxidative stress. We show 
that APEH interacts directly with the DNA single-strand break repair (SSBR) scaffold 
protein XRCC1 and that this interaction mediates recruitment of APEH both into the 
nucleus and at sites of nuclear damage. Moreover, we show that in human cells APEH 
promotes both the repair of chromosomal single-strand breaks (SSBs) and cellular 
resistance to oxidative stress. These data identify APEH as a novel component of the 
DNA damage response, and we suggest that this protease facilitates protein metabolism 
at chromosomal sites of DNA strand breakage. 
2. Materials and Methods 
2.1. Direct fluorescence microscopy. 
1x105 A549 or EM9 cells were seeded on glass cover-slips and after 48-hr transfected 
(Genejuice; Merck) with 1μg peGFP-APEH and 1μg either of pmRFP-C1, pmRFP-
XRCC1, or pmRFP-XRCC1F67A. 24-hr after transfection, cells were washed in PBS and 
treated with 10mM H2O2 (in PBS) for 10min on ice and then incubated in drug-free 
medium at 37°C for the times indicated. Cells were then fixed in PBS containing 4% 
paraformaldehyde for 2-5 min, permeabilized in 0.2% Triton X-100 for 2 min, rinsed 
in PBS, and counterstained with 0.000025% DAPI (4',6'-diamidino-2-phenylindole) for 
5 min. Coverslips were mounted in Vectashield (Vector Labs) and analyzed with a 
Zeiss Axioplan 2 fluorescence microscope. Photographs were taken at a magnification 
of x100 with appropriate filters and where indicated cells scored for sub-cellular 
localisation of GFP-APEH and mRFP-XRCC1.
42.2. Laser microirradiation. 
Human A549 cells were seeded onto glass-bottom dishes (Mattek) and co-transfected 
with peGFP-APEH and pRFP-XRCC1 [16] as described above. 24-hr after 
transfection, cells were incubated for 30 min with 10 μg/ml Hoechst 33258 at 37°C. 
Selected cells were then irradiated with a 351-nm UVA laser focused through a 
40X/1.2-W objective using a Zeiss Axiovert equipped with LSM 520 Meta. UVA 
(10.47 μJ) was introduced to an area of approximately 15μm x 2μm (approximately 
0.35 μJ/m2).
2.3. Subcellular fractionation. 
2x107 A549 cells were harvested by trypsinisation and resuspended in 1ml fractionation 
buffer (15mM Tris-pH7.5, 0.3M sucrose, 15mM NaCl, 5mM MgCl2, 0.1mM EGTA, 
0.5mM DTT, 0.1mM PMSF). An equal volume of fractionation buffer + 0.4% IGEPAL 
was added and the suspension was mixed and incubated on ice for 10 min. The lysate 
was then layered onto 5ml extraction buffer containing 1.2M sucrose and spun at 
10,000g for 20min at 4°C. The top layer containing the cytoplasm was removed and 
the nuclear pellet washed and resuspended in 500μl immunoprecipitation buffer (20mM 
Tris-HCl pH7.5, 10mM EDTA, 100mM NaCl, 1% Triton X-100, 1% Sigma protease 
inhibitor cocktail).
2.4. DNA constructs. 
pACT-23 is a human cDNA library clone encoding OPH/APEH (from now on denoted 
APEH) recovered using XRCC1 as bait (data not shown). To construct pcD2E-FLAG-
APEH, encoding FLAG-tagged APEH, the APEH ORF was amplified from pACT-23 
using forward [5’- gcgaattcagaggagactatggactacaaagatgacgatgacaaggaacgtcagg-3’] 
and reverse [5’-
gcgaattctcagctgcccaagtgtgtgc-3’] primers containing EcoRI restriction sites 
(underlined) and the FLAG ORF (italicised and underlined) and subcloned into 
pTOPO2.1 (Invitrogen) as described by the manufacturer. The EcoRI fragment 
harbouring the FLAG-APEH ORF was then subcloned into the EcoRI site of 
5pcD2E[17,18]. To create peGFP-APEH, the APEH ORF was amplified from pact 23 
using forward [5’-cgaattctgatggaacgtcaggtgctg-3’] and reverse [5’- 
gcggatccgtcagctgcccaagtgtgtgc-3’] primers containing EcoRI and BamHI restriction 
sites (underlined) and cloned into the EcoRI/BamHI sites in peGFP-C3 (Clontech). To 
create pSUPER-APEH, 64mer forward [5’- 
gatccccGGACAAATCGCCCATCAGAttcaagagaTCTGATGGGCGATTTGTCCtttttggaa
-3’] and reverse 
[5’agcttttccaaaaaGGACAAATCGCCCATCAGAtctcttgaaTCTGATGGGCGATTTGTCC
ggg-3’] oligonucleotides (targeted APEH sequence in italics) were annealed and ligated 
into the BglII and HindIII sites of pSUPER (Oligoengine)[19]. To create pcD2E-
FLAG-APEHTR, encoding shRNA targeting resistant FLAG-tagged APEH, pcD2E-
FLAG-APEH was mutated using a Quickchange XL site-directed mutagenesis kit 
(Stratagene) and appropriate forward [5’-gatgctggacaaatcgccGatTCgCtacatccctcaggtg-
3'] and reverse [5’-cacctgagggatgtaGcGAatCggcgatttgtccagcatc-3’] primers and 
confirmed by sequencing (non-coding sequence changes are in capitals). To create 
pFastBac-APEH, the APEH ORF was amplified by PCR from pACT-23 using 
appropriate forward [5’-aaaaggatccatggaacgtcaggtgctgctg-3’] (BamHI site underlined) 
and reverse primers and cloned into pTOPO2.1. A BamHI/NotI fragment encompassing 
the APEH ORF cloned into the BamH1/NotI sites of pFastBac-HT-B (Invitrogen). The 
yeast 2-hybrid constructs pAS-XRCC1 [20], pAS-Lamin [21], pACT-Polβ [22], pACT-
PNKP[22], pAS-XRCC175-212 [23], pAS-XRCC11-159 [23] have been described 
previously. The yeast 2-hybrid constructs pGBKT7-XRCC1F67A, pGBKT7-XRCC1242-
533, and pASLig3α were constructed by standard protocols and pAS-Lamin and pAS-
p53 were kind gifts from Luke Alphey.
2.5. Recombinant human APEH protein and anti-APEH antibody. 
Recombinant human histidine tagged APEH (His-APEH) was generated in Sf9 cells 
using pFastBac-APEH and the Bac-to-Bac baculovirus expression system (Invitrogen). 
Recombinant human His-APEH protein was purified from infected Sf9 by immobilized 
metal chelate chromatography using Ni-NTA agarose (Qiagen) and used as antigen to 
raise rabbit anti-APEH polyclonal antibody SY0999 (Eurogentec). SY0999 was 
affinity purified against recombinant human APEH prior to use.
62.6. APEH depletion by RNA interference. 
For transient APEH depletion, A549 cells were transfected (METAFECTENE PRO, 
Biontex) with a SMARTpool (Thermo Scientific Dharmacon) comprised of the double-
stranded siRNA oligoribonucleotides 5-GCAUGGAGAACAUUCGAUU-3’, 5’-
CAAAAGCACCCACGCAUUA-3’, 5’-GGACAAAUCGCCCAUCAGA-3’ and 5’-
GAGGCUGGCUUUCCUUUCA-3’. For stable APEH depletion, the most effective of 
the four SMARTpool siRNAs was identified and the corresponding 
oligodeoxyribonucleotide sequence (5’-GGACAAATCGCCCATCAGA-3’) cloned 
into the shRNA expression vector pSUPER, creating the shRNA construct pSUPER-
APEH (see above). 3x107 A549 cells were then co-transfected with pCI-puro and either 
empty pSUPER or pSUPER APEH and single transfected clones selected for 6-10 days 
in medium containing 0.8μg/ml puromycin and analysed by immunoblotting for levels 
of APEH depletion. For complementation analysis, a A549 APEH-depleted (clone 3) 
was transfected with empty pCD2E or pCD2E-APEHTR and selected in the presence of 
1.5mg/ml G418 and 0.8g/ml Puromycin for 2-3 weeks. Drug-resistant clones were 
pooled, expanded, and examined by immunoblotting for normal or near-normal levels 
of APEH protein.
2.7. Immunoprecipitation. 
Total cell extract (100μg total protein) or nuclear extract (0.6 mg nuclear protein) from 
the indicated A549 cells was pre-cleared for 2h at 4°C with 60 μl protein G-Sepharose 
beads (Sigma) and the pre-cleared extract then incubated with 5μl of rabbit anti-human 
APEH polyclonal antibody (SY0999) or rabbit IgG (DAKO) on a carousel at 4°C 
overnight in a final volume of 300μl immunoprecipitation (IP) buffer [20 mM Tris-
HCl, pH 7.5, 10 mM EDTA, 100 mM NaCl, 1% Triton X-100, 10% Glycerol, and 1x 
protease inhibitor cocktail (Sigma)], followed by 30 μl protein G-Sepharose beads for 
1 h at 4°C with gentle agitation. Beads were then pelleted in a microfuge, washed with 
IP buffer (3x300μl), and bound proteins eluted by heating in 55 μl of 2x SDS-PAGE 
sample buffer at 90°C for 5 min. Clarified protein samples were fractionated by SDS-
PAGE, transferred to nitrocellulose, and immunoblotted with the anti-phospho-XRCC1 
rabbit polyclonal antibody A300-059A (Bethyl) and the anti-APEH rabbit polyclonal 
7antibody, SY0999. 
2.8. Yeast two-hybrid analysis. 
Pooled populations of Yeast Y190 transformants harbouring the indicated 
pGBKT7/pAS and pACT fusion protein constructs were plated onto minimal media 
lacking Leu and Trp to select for both plasmids or on media additionally lacking 
histidine and containing 25mM 3-aminotriazole (3-AT) to select for activation of the 
His3 reporter gene. In addition, colonies from Leu-, Trp- control plates were examined 
for β-galactosidase (β-gal) activity by filter lift assays, to detect activation of the β-gal 
reporter gene. Equivalent expression levels of pAS DNA binding domain or pACT 
activation domain fusion proteins were confirmed by immunoblotting using the anti-
APEH rabbit polyclonal antibody SY0999 and the anti-XRCC1 rabbit polyclonal 
antibody A300-059A (Bethyl).
2.9. Clonogenic survival assays. 
The indicated A549 cells were plated (500/plate) in 10-cm dishes in duplicate and 
incubated for 4 h at 37°C. Cells were rinsed with PBS (x2) and either mock treated or 
treated with the indicated concentration of either H2O2 in PBS for 15 min at room 
temperature or with methyl methanesulphonate (MMS) or camptothecin (CPT) in 
complete medium for 1 hr at 37°C. After treatment, cells were rinsed with PBS (x2) 
and incubated for 10-14 days in drug-free medium at 37°C to allow formation of 
macroscopic colonies. Colonies were fixed in ethanol (95%), stained with 1% 
methylene blue/70% ethanol and colonies of >50 cells were counted. Survival was 
calculated and expressed graphically using the equation 100 X [mean colony number 
(treated plates)/mean colony number (untreated plates)].
2.10 Alkaline single-cell agarose-gel electrophoresis (alkaline comet assay). 
Sub-confluent monolayers of the indicated A549 cells were trypsinized and diluted to 
4x105 cells/ml immediately prior to mock treatment or treatment with 0.1mM H2O2 in 
PBS for 20 min on ice. Cells were then washed in ice-cold PBS and incubated in fresh 
drug-free medium at 37oC for the indicated repair period. Cells were then collected and 
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quickly mixed with 200μl low melting point agarose type VII (Sigma Aldrich) and 
150ul spread onto 0.6% mini agarose gels on frosted slides on ice. Slides were 
maintained at 4°C for 30 minutes to set and then immersed in ice-cold lysis buffer 
(2.5M NaCl, 100mM EDTA, 1% Triton X-100 pH 10) for 1 hr in the dark. After rinsing 
in ice-cold dH2O (x3), slides were incubated in alkaline electrophoresis buffer (50 mM 
NaCl, 1mM EDTA and 1% DMSO) for 45 min to allow DNA unwinding and then 
subject to electrophoresis for 25 minutes at 12V. Slides were then immersed in 
neutralisation buffer (0.4 M Tris PH 7.0) for at least 3 min at room temperature. Nuclei 
acid was stained with SYBR green (1:10000 dilution, Sigma) and visualised by 
fluorescence microscopy (Nikon Eclipse E400) at 20X magnification. The average 
comet tail moment for 100 cells per sample was determined using Comet Assay III 
software (Perceptive Instruments) and the mean of this value (+/- s.e.m) for at least 
three independent experiments per sample was calculated. Note that the comet tail 
moment is the product of the tail length and the fraction of DNA in the tail.
3. Results
3.1. APEH interacts with XRCC1 in yeast 2-hybrid assays  
A previous yeast 2-hybrid (Y2H) screen of a human cDNA library for proteins that 
interact with the DNA strand break repair protein XRCC1 identified PNKP [24], APTX 
[21], Pol  [20], and DNA ligase III [24] as protein partners. In this same screen, we 
also recovered cDNAs encoding the protein acylpeptide hydrolase (APEH)(Fig.1A). 
Both His3 and βgal reporter genes indicative of protein-protein interaction were 
activated in yeast Y190 cells harbouring pACT-APEH and pAS-XRCC1, whereas 
neither reporter gene was activated in cells harbouring pACT-APEH and either of the 
unrelated control constructs, pAS-Lig3α, pAS-p53, or pAS-Lamin (Fig.1A). Similar 
results were observed with the opposite vector configuration; with XRCC1 and APEH 
expressed as fusion proteins with the GAL4 activation and DNA binding domains, 
respectively (Supplementary Fig.1). 
To confirm the interaction between XRCC1 and APEH biochemically we 
examined whether recombinant human XRCC1 and APEH would co-
9immunoprecipitate from cell extract from Y190 yeast cells harbouring pAS-XRCC1 
and pACT-APEH. Indeed, anti-XRCC1 antibody precipitated both recombinant 
XRCC1 and APEH from this protein extract, whereas control IgG did not (Fig.1B, 
compare lanes 2 & 3). In contrast, anti-XRCC1 antibodies failed to immunoprecipitate 
APEH from yeast cell extract lacking recombinant XRCC1, ruling out that the recovery 
of APEH by anti-XRCC1 antibodies was due to non-specific cross-reactivity of the 
antibody (Fig.1B, compare lanes 4 & 5). 
Finally, additional Y2H analyses employing a variety of truncated or mutated 
derivatives of XRCC1 revealed that APEH interacts with the amino-terminal domain 
(NTD) of XRCC1 (Fig.1C), which is the same region of XRCC1 that interacts with 
DNA polymerase β [25]. Indeed, a single point mutation (F67A) within the XRCC1 
NTD that disrupts interaction with Pol β [26,27] similarly disrupted interaction with 
APEH, confirming that the interaction site in XRCC1 for Pol β and APEH overlap 
(Fig.1C). The lack of interaction between APEH and XRCC1 fragments lacking an 
intact NTD did not reflect instability of the mutant proteins, because these proteins 
retained the ability to interact with PNKP, which binds XRCC1 downstream of the 
NTD (Fig.1C). Together, these data identify APEH as an XRCC1-interacting protein.
3.2 APEH is a component of the cellular response to oxidative stress and is physically 
associated with XRCC1 in mammalian cells.
To examine whether APEH might be a component of the cellular response to oxidative 
stress, we compared the sub-cellular localisation of the GFP-tagged human protein 
before and after treatment of transiently-transfected A549 cells with H2O2. Consistent 
with previous observations [28], ~60% of transiently-transfected cells exhibited 
cytosolic GFP-APEH signal and ~40% exhibited pan-cellular GFP-APEH (Fig.2A). 
However, the fraction of cells with pan-cellular GFP-APEH increased to ~75% 
following treatment with H2O2, suggesting that nuclear import and/or retention of GFP-
APEH increased following oxidative stress (Fig.2A). Similar to mRFP-XRCC1, GFP-
APEH accumulated rapidly at sites of nuclear damage following irradiation with a UVA 
laser (Fig.2B). Together, these data suggest that APEH is a component of the cellular 
response to nuclear damage induced by UVA or H2O2-induced oxidative stress.
We next examined whether APEH is physically associated with XRCC1 in 
human A549 cells. Notably, anti-APEH antibodies co-immunoprecitated XRCC1 from 
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whole cell extract prepared from human A549 cells, whereas control IgG did not 
(Fig.3A). However, because our immunofluorescence experiments suggested that 
APEH and XRCC1 are primarily located in different cellular compartments we 
repeated these experiments using protein extract prepared from highly purified nuclei, 
to rule out that this interaction was an artifact of mixing the subcellular compartments 
during cell lysis. Subcellular fractionation confirmed that APEH and XRCC1 are 
primarily located in different cellular compartments (Fig.3B). Indeed, we failed to 
detect any APEH in nuclear extracts with the antibodies available to us, either before 
or after H2O2 treatment, suggesting that very little if any APEH is present in nuclei. 
Nevertheless, anti-APEH antibodies immunoprecipitated XRCC1 from nuclear extracts 
both before and after H2O2 treatment (~1% and ~3% of total nuclear XRCC1, 
respectively; Fig.3C). Despite this, we still could not detect APEH in the nuclear 
immunoprecipitate (data not shown). Consequently, to confirm that co-
immunoprecipitation of APEH and XRCC1 reflected physical association of these 
proteins, rather than nonspecific binding of XRCC1 by anti-APEH antibody, we 
employed nuclear extract from A549 cells in which APEH was stably depleted by ~90% 
by shRNA (Fig.3D, top). Importantly, whereas, anti-APEH antibodies again 
immunoprecipitated XRCC1 from wild-type A549 cell extract, they failed to do so from 
APEH-depleted cell extract, confirming that a small amount of cellular XRCC1 and 
APEH are physically associated (Fig.3D, bottom). 
3.3. XRCC1 promotes APEH nuclear localisation and recruitment at sites of H2O2-
induced nuclear damage.
XRCC1 interacts with multiple proteins during SSBR including PARP1, Lig3α, PNKP, 
APTX, APLF, and DNA polymerase-β [29]. These interactions serve a variety of 
functions including enzymatic stimulation, stabilisation, and recruitment of the XRCC1 
partners at sites of DNA damage. We thus examined whether interaction with XRCC1 
might be important for the nuclear localisation of APEH, since this protein lacks an 
identifiable nuclear localisation signal. Indeed, the majority of GFP-APEH expressed 
in XRCC1-mutant (EM9) CHO cells localised to the cytoplasm, but co-expression of 
mRFP-XRCC1 resulted in redistribution of this protease to the nucleus, as indicated by 
an increase in the fraction of cells with pan-cellular GFP-APEH (Fig.4A). In contrast, 
co-expression of GFP-APEH with either mRFP or mRFP-XRCC1F67A, which cannot 
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bind the protease, failed to promote nuclear localisation (Fig.4A). We noticed that 
H2O2-treatement increased the level of nuclear GFP-APEH only by a small extent in 
these experiments, presumably because the high level of mRFP-XRCC1 expression 
promoted APEH nuclear localisation even in the absence of H2O2. However, GFP-
APEH did co-localise with mRFP-XRCC1 in sub-nuclear foci following H2O2-
treatment, confirming that GFP-APEH accumulated with XRCC1 at sites of DNA 
strand breakage (Fig.4B, middle panels). Moreover, GFP-APEH failed to accumulate 
into nuclear foci in EM9 cells following H2O2-treatment in the absence of mRFP-
XRCC1 co-expression (Fig.4B, top panels), or if co-expressed with mRFP-XRCC1F67A 
that cannot bind APEH (Fig.4B, bottom panels). We conclude from these experiments 
that the XRCC1 interaction promotes the nuclear localization of GFP-APEH and the 
recruitment of this protease to sites of DNA strand breakage after H2O2 treatment.
3.4. APEH promotes chromosomal SSBR following H2O2 treatment.
Given that APEH is recruited to sites of DNA damage by interaction with XRCC1, we 
examined whether the protease influences the rate of repair of oxidative chromosomal 
DNA strand breaks. Indeed, APEH siRNA significantly reduced the rate at which 
oxidative DNA strand breaks declined in H2O2 treated A549 cells (Fig.5B, top). Whilst 
the defect in SSBR in APEH-depleted cells was quite small it was statistically 
significant.  Moreover, it is consistent with defects in core SSBR proteins such as 
XRCC1 and PNKP, which also only slow the rate of SSBR, by up to ~5-fold [22,30]. 
Similar results were observed in A549 cells that were stably depleted of APEH by 
expression of anti-APEH shRNA, and expression of shRNA-resistant APEH mRNA 
restored both the level of APEH protein and the rate of DNA strand break repair to 
normal (Fig.5B, bottom). Together, these data suggest that APEH promotes the rate of 
repair of DNA strand breaks induced by DNA oxidation. 
3.5. APEH promotes cellular resistance to H2O2
Finally, we examined whether APEH depletion resulted in hypersensitivity to oxidative 
stress, in clonogenic survival assays. Indeed, treatment of human A549 cells with a pool 
of three anti-APEH siRNA molecules (Fig.6A), or stable expression of APEH shRNA 
(Fig.6B), significantly increased sensitivity to H2O2-induced oxidative damage. In 
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contrast, APEH-depleted cells were not hypersensitive to either methyl 
methanosulphonate (MMS) or camptothecin (CPT), genotoxic agents that kill cells by 
mechanisms independent of oxidative stress (Fig.6C & 6D). Moreover, expression of 
shRNA-resistant APEH mRNA restored normal levels of survival in APEH-depleted 
A549 cells following H2O2 treatment, confirming that APEH promotes cellular 
resistance to oxidative stress (Fig.6B). Together, these data demonstrate that APEH 
promotes both the rate of chromosomal DNA strand break repair and cell survival in 
human cells, following H2O2 treatment. 
Discussion
Acylpeptide hydrolase (APEH) is a cytosolic serine protease that removes Nα-
acetylated amino acids from the amino terminus of peptides and degrades oxidised
proteins [8,10,11]. Overexpression of APEH/OPH in COS-7 cells reduces the 
accumulation of oxidised proteins during treatment with H2O2 or paraquat, and APEH 
deletion is implicated in renal carcinoma and small cell lung carcinoma [15,31,32]. In 
addition, inhibition of APEH promotes T cell proliferation [9].  Despite the biological 
importance of APEH, however, the biochemical pathways influenced by this protease 
are unknown. 
Here, we report that APEH is a novel component of the mammalian DNA 
damage response. We found using yeast 2-hybrid analyses that APEH interacts directly 
with the DNA single-strand break repair (SSBR) scaffold protein, XRCC1. The 
interaction with APEH is mediated via the amino terminal domain (NTD) of XRCC1, 
a region that also binds DNA polymerase , suggesting that these two interactions are 
likely to be mutually exclusive. A similar situation is observed for the interactions 
between XRCC1 and PNKP, APLF, and APTX, all of which interact with XRCC1 via 
a centrally located cluster of CK2 phosphorylation sites [16,21,22,33,34]. Intriguingly, 
co-immunoprecipitation experiments revealed that only a small sub-fraction of 
endogenous APEH is bound to XRCC1, and that this sub-fraction increases 
approximately ~3-fold following treatment with H2O2. Consistent with this 
observation, although GFP-tagged APEH was located primarily in the cytoplasm of 
transfected cells, a sub-fraction of GFP-APEH was recruited into nuclei following 
treatment with H2O2, as suggested by the fraction cells that displayed pan-cellular GFP-
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APEH fluorescence.  Over-expression of wild type human RFP-XRCC1 also increased 
the fraction of cells displaying pan-cellular GFP-APEH, even in the absence of H2O2 
treatment, and this was prevented by the F67A mutation that disrupts interaction with 
APEH. We do not yet know if the H2O2-mediated increase in pan-cellular GFP-APEH 
is also mediated by interaction with XRCC1, but this seems likely. Similarly, we do not 
know why H2O2 treatment and/or XRCC1 over-expression increased the fraction of 
cells with pan-cellular APEH, rather than increasing the level of nuclear GFP-APEH in 
all cells. One possibility is that other factors also influence the sub-cellular localisation 
of APEH, such as cell cycle position and/or sub-cellular localization of other binding 
partners.  Finally, we noted that treatment with leptomycin B also promoted an increase 
in the fraction of A549 cells with pan-cellular GFP-APEH (unpublished observations), 
suggesting that the cytoplasmic localisation of GFP-APEH is promoted by nuclear 
export. 
Importantly, a sub-fraction of GFP-APEH accumulated at sites of nuclear 
damage induced by either UVA laser or H2O2. In the latter case, we demonstrated that 
this event was XRCC1 dependent, since GFP-APEH relocalised into H2O2-induced 
nuclear foci when co-expressed with wild type RFP-XRCC1 but not with RFP-
XRCC1F67A. We employed UVA laser and H2O2 in these experiments because of the 
established role of APEH in degrading oxidised proteins, but we cannot rule out that 
APEH plays a more general role at other types of DNA strand breakage. Consistent 
with these data, depletion of APEH in human A549 cells reduced the rate of 
chromosomal DNA strand-break repair following H2O2 treatment. Whilst the impact of 
APEH depletion on DNA strand break repair was mild it is important to note that the 
loss of even core components of this process such as PARP1 and XRCC1 slow SSBR 
only ~5-fold, attesting to the enzymatic resilience and/or redundancy within this 
pathway [22,30]. Because the majority (>99.5%) of DNA strand breaks induced by 
DNA oxidation are SSBs [35] it is likely that the reduced rate of DNA strand break 
repair in APEH depleted cells reflects a reduced rate of SSBR. This conclusion is 
consistent with the interaction of APEH with XRCC1, since the latter is a key regulator 
of chromosomal SSBR [29]. In addition to accelerating SSBR, APEH was also required 
for cellular resistance to oxidative stress, as measured by the hypersensitivity of APEH-
depleted cells to H2O2 in clonogenic survival assays. This was not an off-target effect 
of shRNA because stable expression of shRNA-resistant APEH restored normal levels 
of resistance to H2O2. In contrast, we did not observe hypersensitivity to either methyl 
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methanesulphonate (MMS) or camptothecin (CPT), two genotoxins that induce SSBs 
independently of oxidative stress. 
What role might APEH play at chromosomal SSBs? APEH is important for 
degrading oxidised membrane and cytoplasmic proteins [10,28,32,36]. However, a 
recent proteomic analysis identified a broad range of both nuclear and cytoplasmic 
proteins that exhibited altered levels of Nα-acetylation if APEH activity was inhibited, 
suggesting that the number and distribution of APEH substrates may be much larger 
than previously thought [9]. Our finding that a sub-fraction of APEH is sequestered at 
sites of nuclear DNA damage is consistent with this possibility and raises the possibility 
that this protease processes one or more protein components of damaged chromatin. 
One possibility is that APEH modulates chromatin compaction at chromosomal SSBs 
by controlling the Nα-acetylation status of one or more chromatin regulators, analogous 
to the role played by Nα-acetylation on Orc1 and Sir3 function in budding yeast [3-6]. 
Perhaps consistent with this, we have observed that APEH over-expression represses 
silencing of a telomeric URA3 gene in budding yeast, silencing of which is known to 
be dependent on Nα-acetylation of Orc1 and Sir3, is consistent with this model 
(unpublished observations). 
An alternative model for APEH function is that the enzyme is required for 
removal or degradation of oxidised proteins during SSBR. Protein oxidation may be 
particularly prevalent at sites of SSBs, because the elevated concentration of ADP-
ribose arising from poly (ADP-ribose) synthesis at SSBs can lead to protein 
glycoxidation and oxidation [37-40]. Oxidised chromatin proteins might require 
removal and degradation not only to allow access for repair, but also to prevent them 
from perturbing chromatin function and the epigenetic code. A mechanism for 
degrading oxidised histone proteins that employs the 20S proteosome has been 
described previously [41,42]. Whilst APEH has been reported to regulate the activity 
of the proteasome [14], it is possible that APEH provides an alternative mechanism for 
degrading oxidised histones, since it has also been reported to function independently 
of the proteosome [28]. It is also possible that the acylpeptide hydrolase and oxidised 
protein hydrolase activities of APEH function synergistically in this respect, since 
removal of the Nα-acetylated terminal amino acid from proteins has been reported to 
promote protein instability and degradation.
In summary, we have identified acylpeptide hydrolase (APEH) as a novel 
component of the mammalian DNA damage response. We show that APEH is recruited 
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at sites of DNA strand breakage induced by H2O2 by direct interaction with XRCC1, 
and that APEH promotes both the rapid repair of chromosomal SSBs and cellular 
resistance to H2O2-induced oxidative stress. Based on these data, we speculate that 
APEH is required during the repair of SSBs to promote the metabolism or turnover of 
chromatin proteins at sites of DNA breakage.
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Figure legends
Fig.1. XRCC1 Interacts with APEH in Yeast 2-hybrid Assays. [A] Yeast Y190 cells 
harbouring the indicated GAL4 activation domain (pACT) and DNA binding domain 
(pAS) expression constructs encoding full-length XRCC1, APEH, DNA ligase III 
(Lig3), DNA polymerase  (Pol), or Lamin, were examined for activation of the 2-
hybrid reporter genes His3 and LacZ (‘βgal’) as described in Experimental Procedures.  
[B], Anti-XRCC1 and control IgG immunoprecipitates recovered from cell extract from 
Y190 cells harbouring pAS-XRCC1 and pACT-APEH (lanes 2, 3 & 4), or as an 
additional negative control pAS-Lig3 and pACT-APEH (lane 5), were immunoblotted 
for XRCC1 and APEH. [C] Top, Yeast Y190 cells harbouring the indicated pACT full-
length expression constructs and DNA binding domain (pAS or pGBKT7; “pGB”) 
truncated XRCC1 expression constructs were examined for activation of the 2-hybrid 
reporter genes His3 and LacZ (‘βgal’), as described above. Bottom, Cartoon 
summarizing the truncated/mutated XRCC1 proteins employed to map the site of 
APEH interaction. Interaction (+) or lack of interaction (-) with APEH as measured by 
activation of the His3 and LacZ reporter genes is indicated. 
Fig.2. Relocalisation of GFP-APEH in response to UVA laser or H2O2-induced 
damage. A549 transiently transfected with peGFP (GFP) or peGFP-APEH (GFP-
APEH) were mock-treated or treated with 10mM H2O2 on ice for 10 min followed by
incubation in drug-free medium at 37⁰C for 20 min or 1 hr. GFP proteins were 
16
visualised in fixed cells by direct immunofluorescence microscopy and scored for sub-
cellular localisation (Bottom). Top, representative images of cytoplasmic (left) and pan-
cellular (right) GFP-APEH. Note that we failed to detect cells with exclusively nuclear 
GFP-APEH (blue). [B] A549 cells transiently transfected with peGFP-APEH and 
pmRFP-XRCC1 were irradiated with a UVA laser and visualised by fluorescent 
microscopy before and 2-min after UVA irradiation. Representative images are 
presented. 
Fig.3. APEH and XRCC1 physically interact. [A], Whole-cell extract from human 
A549 cells was immunoprecipitated with rabbit IgG or anti-APEH rabbit polyclonal 
antibody and aliquots of the input (2%; ‘In’), unbound column flow-through (3%;’U’), 
final column wash (3%; ‘W’), and immunoprecipitate (67%; ‘P’) were fractionated by 
SDS-PAGE and immunoblotted for APEH (top) and XRCC1 (bottom). [B] Top; 
Aliquots (~15μg total protein) of whole-cell, cytoplasmic, and nuclear extract from 
A549 cells was fractionated by SDS-PAGE and immunoblotted for APEH, XRCC1, 
and α-tubulin. [C] Nuclear extract from mock-treated (top) or H2O2-treated (bottom) 
A549 cells was immunoprecipitated with rabbit IgG or anti-APEH rabbit polyclonal 
antibody and aliquots of the input (2%; ‘In’), unbound material (2%; ‘U’), final column 
wash (3%; ‘W’), and immunoprecipitate (67%; ‘P’) were fractionated by SDS-PAGE 
and immunoblotted for XRCC1. [D] Top, Aliquots of whole cell extract from wild type 
and APEH-depleted A549 cells were fractionated by SDS-PAGE and immunoblotted 
for APEH and actin. Bottom, nuclear extract from H2O2-treated wild type or APEH-
depleted A549 cells was immunoprecipitated with anti-APEH rabbit polyclonal 
antibody and aliquots of the indicated samples fractionated and immunoblotted for 
XRCC1 as described above. 
Fig.4. XRCC1 promotes APEH nuclear localisation and recruitment at sites of 
H2O2-induced nuclear damage. [A] Sub-cellular localisation of GFP-APEH in 
XRCC1-mutant EM9 CHO cells co-transfected with mRFP ('RFP'), mRFP-XRCC1 
('RFP-XRCC1'), or mRFP-XRCC1F67A (‘RFP-F67A’) in the absence of H2O2 treatment 
(‘Unt’) or 20 min or 60 min following H2O2 treatment. [B] Sub-nuclear localisation of 
GFP-APEH in XRCC1-mutant EM9 CHO cells co-expressing mRFP-XRCC1 or 
mRFP-XRCC1F67A in the absence of H2O2 treatment and 20 min after H2O2 treatment. 
Representative images are shown.
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Fig.5. APEH promotes chromosomal SSBR following oxidative stress. [A] DNA 
strand breaks measured in mock-transfected A549 cells (‘A549’) and A549 cells 
transiently transfected with APEH siRNA (‘KD’) prior to (‘untreated’) or at the 
indicated times after treatment with 0.1mM H2O2. DNA strand breaks were quantified 
as the mean comet tail moment of 100 cells per data point and are the average (+/- 
SEM) of five independent experiments. Data for A549 versus KD were compared by 
two-way ANOVA with replication (p=0.008). Significant data points (identified by 
Bonferroni multiple comparisons tests) are indicated by asterisks. [C] DNA strand 
breaks measured as above in A549 cells, A549 cells stably transfected with APEH 
shRNA construct (‘KD’), and A549 cells stably-transfected with APEH shRNA 
construct and either empty vector (‘KD+V’) or expression construct encoding shRNA-
resistant APEH (‘KD+APEH’). Data are mean (±SEM) of four independent 
experiments and data sets were compared pair wise by two-way ANOVA with 
replication. Significantly different data sets were KD versus KD+APEH, p=0.03 and 
KD-V versus KD+APEH, p=0.047. Significant data points (identified by Bonferroni 
multiple comparisons tests) are indicated by asterisks.
Fig.6. APEH promotes cellular resistance to oxidative stress. [A] Clonogenic 
survival following H2O2 treatment in mock-transfected A549 cells (‘Control’) and 
A549 cells transiently transfected with APEH siRNA. Data are the mean (+/- SEM) of 
at least three independent experiments. [B] Clonogenic survival following H2O2 
treatment in A549 cells, A549 cells stably transfected with APEH shRNA construct 
(‘KD’), and A549 cells stably-transfected with APEH shRNA construct and either 
empty vector (‘KD+V’) or expression construct encoding shRNA-resistant APEH (‘KD 
+APEH’).  Data as above. [C] Clonogenic survival following treatment with methyl 
methanesulphonate (MMS) in A549 cells (‘control’) and A549 cells stably transfected 
with APEH shRNA construct (‘KD’). Data as above. [D] Clonogenic survival 
following treatment with camptothecin (CPT) in A549 cells (‘control’) and A549 cells 
stably transfected with APEH shRNA construct (‘KD’). Data as above. 
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